

---

## New article about CombiGene in Biostock

Biostock summarizes the latest news from CombiGene and talks to CEO Jan Nilsson about the importance of the many milestones and the continued plan for the epilepsy project CG01.

<https://www.biostock.se/en/combigene-one-step-closer-to-clinical-trials/>

### Contacts

---

Jan Nilsson, CEO

Phone: +46 (0)704 66 31 63

jan.nilsson@combigene.com

Bert Junno, Chairman of the board

Phone: +46 (0)707 77 22 09

bert.junno@combigene.com

[www.combigene.com](http://www.combigene.com)

CombiGene AB (publ) Medicon Village, SE-223 81 Lund, Sweden

[info@combigene.com](mailto:info@combigene.com)

### About CombiGene

---

CombiGene's vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies.

CombiGene's business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99, [info@fnca.se](mailto:info@fnca.se).

*CombiGene's lead project CG01 has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 823282*

### Attachments

---

[New article about CombiGene in Biostock](#)